BioSpecifics Technologies Corp. (BSTC) EPS Estimated At $0.39

February 24, 2018 - By Adrian Mccoy

 BioSpecifics Technologies Corp. (BSTC) EPS Estimated At $0.39
Investors sentiment decreased to 1.08 in 2017 Q3. Its down 0.15, from 1.23 in 2017Q2. It fall, as 10 investors sold BioSpecifics Technologies Corp. shares while 27 reduced holdings. 16 funds opened positions while 24 raised stakes. 3.70 million shares or 3.67% less from 3.84 million shares in 2017Q2 were reported.
Ajo L P holds 10,951 shares. Century has 25,607 shares for 0% of their portfolio. Moreover, California State Teachers Retirement System has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Meeder Asset, a Ohio-based fund reported 81 shares. Acadian Asset Management Lc has 0.03% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Sg Americas invested in 3,473 shares. Los Angeles And Equity Rech, California-based fund reported 4,784 shares. 27,825 are owned by Tiaa Cref Inv Mgmt Limited Liability Corp. Chicago Equity Limited Liability Corp holds 0.02% in BioSpecifics Technologies Corp. (NASDAQ:BSTC) or 13,835 shares. Clarivest Asset Limited Liability Corporation holds 24,773 shares or 0.03% of its portfolio. Panagora Asset owns 9,532 shares. Balyasny Asset Ltd Liability Corp invested in 0% or 5,204 shares. Moreover, Wells Fargo & Mn has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Moreover, Northern Trust Corp has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). 5,258 are owned by Credit Suisse Ag.

Analysts expect BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report $0.39 EPS on March, 21.They anticipate $0.01 EPS change or 2.50 % from last quarter’s $0.4 EPS. BSTC’s profit would be $2.80M giving it 25.65 P/E if the $0.39 EPS is correct. After having $0.37 EPS previously, BioSpecifics Technologies Corp.’s analysts see 5.41 % EPS growth. The stock increased 3.60% or $1.39 during the last trading session, reaching $40.02. About 14,287 shares traded. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 49.91% since February 24, 2017 and is uptrending. It has outperformed by 33.21% the S&P500.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Ratings Coverage

Among 2 analysts covering BioSpecifics Technologies Corp (NASDAQ:BSTC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioSpecifics Technologies Corp had 6 analyst reports since March 8, 2016 according to SRatingsIntel. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) earned “Buy” rating by H.C. Wainwright on Monday, December 11. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) has “Buy” rating given on Tuesday, December 26 by H.C. Wainwright. On Monday, November 13 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was initiated on Wednesday, February 7 by H.C. Wainwright. On Tuesday, March 8 the stock rating was initiated by Rodman & Renshaw with “Buy”. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) earned “Buy” rating by H.C. Wainwright on Thursday, August 10.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $287.71 million. The firm offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 25.17 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: which released: “BioSpecifics Technologies Corp.” on March 26, 2017, also with their article: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of …” published on November 17, 2016, published: “BioSpecifics Technologies Corp. Has A 6-Year Expiration Date” on August 03, 2016. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: and their article: “News BioSpecifics Technologies Corp.BSTC” published on February 12, 2011 as well as‘s news article titled: “Biospecifics Technology Corp.: Underfollowed And Undervalued” with publication date: April 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: